PURR — Hyperliquid Strategies Inc
NASDAQ · Biotechnology · Biotechnology
- Latest Close
- $6
- 30-Day Move
- +85.8%
- Market Cap
- $653M
- Shares Outstanding
- 123,970,000
- Latest Revenue
- $500,000
Analyst consensus: Buy · 8 analysts
Hyperliquid Strategies Inc
A read-only Alphactor snapshot forHyperliquid Strategies Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-24
Topline snapshot
Latest Close
$6
30-Day Move
+85.8%
Market Cap
$653M
Shares Outstanding
123,970,000
Latest Revenue
$500,000
$6.00
+85.8%last 90 delayed daily bars
90D High
$6.88
90D Low
$3.01
Avg Volume
3,922,416
PURR is up 85.8% over the last 30 trading days shown on this page.
Latest operating income is $-3M, which helps anchor the headline ratios with an actual earnings figure.
Dark Pool Short %
23.8%
Latest Close
$6
30-Day Move
+85.8%
Market Cap
$653M
Shares Outstanding
123,970,000
Latest Revenue
$500,000
Revenue
$500,000
Gross Profit
--
Operating Income
$-3M
Net Income
$-304M
Gross Margin
--
Net Margin
--
Current Ratio
--
Debt / Equity
--
Altman Z
--
N/A
Piotroski
0
Insufficient data
Cash Conversion
--
Rule of 40
--
Insufficient data
After signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-01 | Rosengren Eric S | A | 7,367 | $0.00 |
| 2026-04-01 | Bhatt Nailesh | A | 2,455 | $0.00 |
| 2026-04-01 | KING THOMAS C. | A | 7,367 | $0.00 |
| 2026-04-01 | LEIBOWITZ LAWRENCE E | A | 3,274 | $0.00 |
| 2026-02-09 | Rosengren Eric S | A | 40,789 | $0.00 |
| 2026-02-09 | Bhatt Nailesh | A | 40,789 | $0.00 |
| 2026-02-09 | KING THOMAS C. | A | 40,789 | $0.00 |
| 2026-02-09 | TUDER JEFFREY | A | 40,789 | $0.00 |
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2,567,220 | 0.02% | 2026-03-31 |
| Direxion Shares ETF Trust-Direxion Daily S&P Biotech Bull 3X ETF | 132,782 | 0.00% | 2026-03-31 |
| Saba Capital Income & Opportunities Fund | 107,409 | 0.00% | 2026-01-31 |
| Saba Capital Income & Opportunities Fund II | 64,760 | 0.00% | 2026-01-31 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 12,530 | 0.00% | 2025-12-31 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Geode Capital Management
Filed 2026-02-09
$291,969
--
Vanguard Group
Filed 2026-01-29
$68,626
--
4.13
Consensus
Buy—
—
—
8
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.